Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	15.23B
Revenue (ttm)	4.65B
Net Income (ttm)	348.26M
Shares Out	529.26M
EPS (ttm)	0.66
PE Ratio	43.37
Forward PE	22.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,171
Average Volume	216,253
Open	29.00
Previous Close	28.78
Day's Range	28.64 - 29.00
52-Week Range	27.80 - 47.30
Beta	1.50
RSI	39.72
Earnings Date	Feb 12, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR